Rose McNulty

Population demographics and prevention efforts are key drivers of influenza burden, according to Marco del Riccio, MD.

Traditional Chinese medicine relies on nonlinear, unstructured data, but a new report suggests its practitioners can still benefit from machine learning, including in the treatment of idiopathic pulmonary fibrosis.

DeFi trial results show that continuous nirogacestat provides durable tumor control, ongoing shrinkage, sustained symptom improvement, and a stable safety profile over several years.

Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and updated data presented at conferences.

Scott Soefje, PharmD, outlines proactive financial screening, flexible payment models, and stronger academic-community partnerships for advanced cancer care.

Acute exacerbations of chronic rhinosinusitis are poorly defined and often overtreated, calling for standardized diagnostic criteria and more evidence-based management.

The most-read content for HIV focused on funding cuts to HIV aid and research and satisfaction with telemedicine for HIV care.

The most-read articles focused on soft tissue sarcoma research, including innovative biomarkers, treatment strategies, and multidisciplinary care challenges.

The 2025 Community Oncology Conference, hosted by COA, reflected a commitment to patient-centered care, access, and innovation in community oncology.

The top ophthalmology content included FDA approvals, FDA complete response letters, and new associations between cataracts and antioxidant index.

In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable toxicity in older, chemotherapy-ineligible patients with LBCL.

A reimbursable, team-based remote blood pressure monitoring program significantly improved hypertension control in patients with multiple chronic conditions.

Respiratory syncytial virus (RSV) remains a leading cause of acute bronchitis in children, but new research may enable earlier intervention.

In-home step training for multiple sclerosis showed no improvement in ankle proprioception or muscle performance, highlighting challenges in exercise adherence.

Explore the latest breakthroughs in allergy treatments, including FDA approvals and emerging therapies that enhance patient care and address systemic challenges.

Chronic inducible cold urticaria is rare, but a new study suggests it can have significant impacts on patients’ daily lives.

Our top 5 heart failure content of 2025 include FDA approvals, GDMT optimization, risk markers like LBBB and SDOH, and value-based care models improving outcomes in heart failure.

Scott Soefje, PharmD, MBA, BCOP, of Mayo Clinic, discusses how payer-provider collaboration and pharmacist-led management can help improve oncology care.

Our conference coverage featured updates on clinical trials testing new treatments for NSCLC, bladder cancer, and breast cancer.

The FDA approves Wegovy, the first oral GLP-1 pill, offering a new weight loss solution for those struggling with obesity and overweight.

With a follow-up of up to 6 years, the median progression-free survival for long-term extension participants was 52.5 months.

The benefit of trabectedin plus olaparib to all-comers with soft tissue sarcoma was marginal, but the response was more pronounced in certain subgroups.

Patients with DLBCL who were treated with R-CHOP and quickly relapsed or were refractory to therapy had poor outcomes on second-line therapy.

Interim GLOVe trial results show that the frontline combination of glofitamab, lenalidomide, and venetoclax induces rapid, deep, and predominantly MRD-negative remissions in high-risk mantle cell lymphoma with manageable toxicity.

The approval was based on the pivotal phase 3 FIBRONEER-ILD trial, in which nerandomilast slowed lung function decline in PPF and had similar discontinuation rates to placebo.

The 2025 American Thoracic Society International Conference brought advancements in pulmonary medicine and highlighted the need for health equity reforms.

Community oncology practices can enhance their presence in the community by offering innovative service lines such as multispecialty infusions, and by offering enrollment assistance for better outcomes.

Reflect on the challenges in health equity, care access, and policy shifts impacting health insurance and clinical research in 2025.

There is no cure for chronic lymphocytic leukemia, but an array of new therapeutic strategies are improving outcomes for patients.

Clascoterone 5% topical solution shows promise as a new treatment for male androgenetic alopecia, offering significant hair growth improvements with minimal side effects.